74 studies on 50 compounds
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies This week, Cybin Inc. (CYBN) completed
October 19, 2021
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies This week, Cybin Inc. (CYBN) completed
New Research Hints at a Link Between Psychedelics and Improved Heart Health Psychedelics improve mental
GOP Pennsylvania Lawmaker Files Psilocybin Research Bill For Veterans And First Responders The push for
Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead
Psilocybin Study for Tobacco Gets Federal Funding After half a century, the US federal government
Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial Dr. Matthew Johnson
Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
Seattle Overdose Task Force Calls for Decriminalization of All Drugs Will Seattle be the next
This Psychedelics Stock Could Grow 300% In One Year Experts predict major growth for this
Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder To Include Additional Behavioral
Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption If
B.More Advances FDA Drug Trials using Psilocybin to Treat Alcoholism 70% of alcoholics relapse within
Magic mushrooms: UAB studying benefits for addiction and pain Dr. Peter Hendricks, a researcher at
Dr. Jennifer Miller | Principal Investigator, Tryp Therapeutics Tryp Therapeutics Inc. (TRYP), is conducting a
New York Bill Would Create State-Sponsored Psychedelics Research Institute A new bill proposed in New
Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003 Cybin announced that its proprietary
More Than A Trip: Psychedelic Drugs Being Used To Help People Quit Smoking In Just